SLC5A2 and myotonic dystrophy type 2: The 2019 version of ‘Management of Hyperglycemia in Type 2 Diabetes’, a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes, offers more direction on when to prescribe SGLT2 inhibitors or GLP‐1 RAs in patients with DM2 at high or very high cardiovascular risk [19].